From: The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
Benign No.(%)
81(40.10%)
benign glands
31(15.35%)
Inflammation
26(12.87%)
HGPIN
17(8.42%)
ASAP
4(1.98%)
Atrophy
3(1.49%)
PCa No.(%)
121 (59.90%)
GS 6
16 (7.92%)
GS 7
30 (14.85%)
GS 8–10
75 (37.13%)